Plasma concentrations of dasatinib have a clinical impact on the frequency of dasatinib dose reduction and interruption in chronic myeloid leukemia: an analysis of the DARIA 01 study

BACKGROUND: Dasatinib has shown promising anti-leukemic activity against chronic myeloid leukemia (CML). However, patients receiving dasatinib frequently require dose reductions and treatment interruptions (treatment alteration). METHODS: We prospectively analyzed the frequency and significance of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Mizuta, Shuichi, Sawa, Masashi, Tsurumi, Hisashi, Matsumoto, Kana, Miyao, Kotaro, Hara, Takeshi, Takahashi, Takeshi, Sakemura, Reona, Kojima, Hiroshi, Kohno, Akio, Oba, Mari S., Morita, Satoshi, Sakamoto, Junichi, Emi, Nobuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6154123/
https://www.ncbi.nlm.nih.gov/pubmed/29845477
http://dx.doi.org/10.1007/s10147-018-1300-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6154123/
https://www.ncbi.nlm.nih.gov/pubmed/29845477
http://dx.doi.org/10.1007/s10147-018-1300-9

Ejemplares similares